Grant Detail
The grant detail shows the name of the PI, active dates of the project, the funding institute and the abstract of the grant. This abstract is what is used to create the fingerprint of the grant. If any publications referencing this grant are found in the data, they will be listed here as well.
Epidemiology of Biomarkers of Risk and Progression in LOAD
1 May 2010 - 30 April 2015
NATIONAL INSTITUTE ON AGING
Total Funding: $ 3,960,971
DESCRIPTION (provided by applicant): The overall theme of this new project is to establish and validate blood- and imaging-based biomarkers associated with the risk and progression of late onset Alzheimer's disease (LOAD), mild cognitive impairment (MCI) and the rate of cognitive decline in late life. We also propose to develop a framework with which we can understand how biomarkers interact and how they fit into the temporal sequence from healthy aging to dementia. This proposal is built on two decades of epidemiological research and systematic data collection in the multi-ethnic, Washington Heights, Hamilton Heights, Inwood, Columbia Aging Project (PO1AG07232). Over the past 20 years, we have investigated the rates of LOAD, MCI and cognitive decline in this urban community in northern Manhattan. We have investigated environmental, health-related and genetic risk factors of disease and predictors of disease progression by collecting longitudinal data on cognitive performance, emotional health, independence in daily activities, blood pressure, anthropometric measures, cardiovascular status and selected biomarkers in this elderly, multi-ethnic cohort, including lipids, amyloid peptides, sex hormones, homocysteine, insulin and C-reactive protein (CRP), and MRI. We have reported that the rates of disease and the frequency of disease risk factors vary across ethnic groups. We have identified one of the largest, multi-ethnic groups of incident LOAD cases facilitating studies of disease progression. Clinical and genetic data as well as biological resources are present for several thousand individuals. Biomarkers, cellular, biochemical or molecular alterations measurable in human tissues, cells, or fluids or by radiological means, are typically chosen because they are directly or indirectly in the causal pathway of disease. The emergence of structural and functional brain imaging has revolutionized epidemiological studies, particularly those using biomarkers for Alzheimer's disease. Positron emission tomography brain imaging using 11C Pittsburgh compound B is considered an in vivo measure of brain amyloid plaque load, while structural MRI, especially changes in brain volume and cerebral blood flow (CBF), can be considered an in vivo measures of neurodegeneration. In this new proposal, we will focus this longitudinal investigation on two sets of blood biomarkers that not only show consistent and robust associations to the risk of LOAD, MCI and cognitive decline, but that address the putative mechanisms related to amyloid burden and insulin resistance. We will take full advantage of the prospective design in this multi-ethnic cohort and the clinical, biological and brain imaging data collected to address six major hypotheses. The first two primary specific aims consider blood biomarkers as not only predictors of cognitive decline, MCI, LOAD and LOAD progression, but also as intermediate steps in the disease pathway, including neurodegeneration and cerebrovascular burden (MRI) and amyloid plaque load (PIB). In the last primary specific aim, brain imaging variables are predictors and cognitive decline, MCI, LOAD as well as LOAD progression are main outcomes. PUBLIC HEALTH RELEVANCE: There is general agreement that developing biomarkers that measure the risk of cognitive decline, LOAD and related diseases as well as the rate of disease progression would greatly enhance clinical, epidemiological, and pharmacological research. Furthermore developing biomarkers that can be easily obtained using standard and acceptable medical procedures such as blood samples or brain imaging would facilitate their use in developing methods to delay or prevent disease in the general community. Therefore the potential public health impact of developing reliable and valid biomarkers in a multi-ethnic community is a major benefit of this proposed investigation.
13 Resulting Publications
-
1.
2013Edward D Huey; Peter L Nagy; Laura Rodriguez-Murillo; Masood Manoochehri; Jill Goldman; Jeffrey Lieberman; Maria Karayiorgou; Richard Mayeux
C9ORF72 repeat expansions not detected in a group of patients with schizophrenia.
Neurobiology of aging 2013;34(4):1309.e9-10. -
2.
2013Joshua Z Willey; Nikolaos Scarmeas; Frank A Provenzano; José A Luchsinger; Richard Mayeux; Adam M Brickman
White matter hyperintensity volume and impaired mobility among older adults.
Journal of neurology 2013;260(3):884-90. -
3.
2012Lawrence S Honig; Min Suk Kang; Nicole Schupf; Joseph H Lee; Richard Mayeux
Association of shorter leukocyte telomere repeat length with dementia and mortality.
Archives of neurology 2012;69(10):1332-9. -
4.
2012Christiane Reitz; Christopher Conrad; Katherine Roszkowski; Robert S Rogers; Richard Mayeux
Effect of genetic variation in LRRTM3 on risk of Alzheimer disease.
Archives of neurology 2012;69(7):894-900. -
5.
2012José A Luchsinger; Derek Cheng; Ming Xin Tang; Nicole Schupf; Richard Mayeux
Central obesity in the elderly is related to late-onset Alzheimer disease.
Alzheimer disease and associated disorders 2012;26(2):101-5. -
6.
2012Sandra Barral; Israel Fernández-Cadenas; Joshua C Bis; Joan Montaner; Arfan M Ikram; Lenore J Launer; Myriam Fornage; Helena Schmidt; Adam M Brickman; Sudha Seshadri; et al.
No association of ALOX5AP polymorphisms with risk of MRI-defined brain infarcts.
Neurobiology of aging 2012;33(3):629.e1-3. -
7.
2012Mirjam I Geerlings; Adam M Brickman; Nicole Schupf; Davangere P Devanand; José A Luchsinger; Richard Mayeux; Scott A Small
Journal of Alzheimer's disease : JAD 2012;30(1):75-82. -
8.
2011Richard Mayeux; Nicole Schupf
Blood-based biomarkers for Alzheimer's disease: plasma Aβ40 and Aβ42, and genetic variants.
Neurobiology of aging 2011;32 Suppl 1():S10-9. -
9.
2011Nikolaos Scarmeas; Jose A Luchsinger; Adam M Brickman; Stephanie Cosentino; Nicole Schupf; Ming Xin-Tang; Yian Gu; Yaakov Stern
Physical activity and Alzheimer disease course.
The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2011;19(5):471-81. -
10.
2011Christiane Reitz; Carol Brayne; Richard Mayeux
Epidemiology of Alzheimer disease.
Nature reviews. Neurology 2011;7(3):137-52. -
11.
2011Nikolaos Scarmeas; José A Luchsinger; Yaakov Stern; Yian Gu; Jing He; Charlie DeCarli; Truman Brown; Adam M Brickman
Mediterranean diet and magnetic resonance imaging-assessed cerebrovascular disease.
Annals of neurology 2011;69(2):257-68. -
12.
2011Christiane Reitz; Shinya Tokuhiro; Lorraine N Clark; Christopher Conrad; Jean-Paul Vonsattel; Lili-Naz Hazrati; András Palotás; Raphael Lantigua; Martin Medrano; Ivonne Z Jiménez-Velázquez; et al.
Annals of neurology 2011;69(1):47-64. -
13.
2010Adam M Brickman; Christiane Reitz; José A Luchsinger; Jennifer J Manly; Nicole Schupf; Jordan Muraskin; Charles DeCarli; Truman R Brown; Richard Mayeux
Long-term blood pressure fluctuation and cerebrovascular disease in an elderly cohort.
Archives of neurology 2010;67(5):564-9.
Scientific Context
This section shows information that has been computed by using the fingerprint of the grant, including related publications, related experts and related grants - all with fingerprints representing significant amounts of overlap between their fingerprint and this grant. The red dots indicate whether those experts or terms actually appear within this grant, showing potential and actual connections.
Related Grants
Related Publications
Related Topics
Appears in this Publication
Related Experts
Author of this Publication
-
Internal ExpertsPublications

